Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
Primary Purpose
Cervical Cancer, Precancerous Condition
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Colposcopic biopsy
Light-Scattering Spectroscopy
Sponsored by
About this trial
This is an interventional diagnostic trial for Cervical Cancer focused on measuring cervical cancer, cervical intraepithelial neoplasia
Eligibility Criteria
Inclusion Criteria: Subjects will be individuals 18 years of age or older, who have voluntarily responded to advertisement in the form of posted flyers or word of mouth. Subjects must sign an informed consent indicating awareness of the investigational nature of this study. Exclusion Criteria: 1) Pregnant individuals will be ineligible for this study.
Sites / Locations
- M. D. Anderson Cancer Center at University of Texas
- British Columbia Cancer Agency - Vancouver Cancer Centre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fluorescence Spectroscopy
Arm Description
Outcomes
Primary Outcome Measures
Fluorescent Measurements of Cervix
Two fluorescent measurements of cervix, approximately 2.5 minutes each: 1)colposcopically normal columnar site, and 2) a colposcopically normal squamous site.
Secondary Outcome Measures
Full Information
NCT ID
NCT00084903
First Posted
June 10, 2004
Last Updated
August 1, 2012
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT00084903
Brief Title
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
Official Title
Pathological Correlation of Colposcopically Directed Biopsies to Fluorescence EEM of the Normal Human Cervix
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
April 1998 (undefined)
Primary Completion Date
July 2007 (Actual)
Study Completion Date
February 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
RATIONALE: New diagnostic procedures such as fluorescence and reflectance spectroscopy (shining light on tissue and measuring patterns of light reflected) may improve the ability to noninvasively detect cervical intraepithelial neoplasia and dysplasia.
PURPOSE: This diagnostic trial is studying how well fluorescence and reflectance spectroscopy during colposcopy work in detecting cervical intraepithelial neoplasia and dysplasia in healthy participants with a history of normal Pap smears.
Detailed Description
OBJECTIVES:
Identify potential improvements in noninvasive methods of diagnosing dysplasia and neoplasia of the cervix using fluorescence and reflectance spectroscopy in healthy participants with a history of normal pap smears.
Determine the reflection and fluorescence spectra of in vivo samples of the normal human cervix.
Refine the detection of cervical lesions by fluorescence spectroscopy in these participants using improved classification of normal columnar tissue and non-neoplastic tissue with inflammation.
Determine and validate the wavelength selections for spectroscopic diagnosis derived from in vitro measurements from these participants.
Compare specific tissue sections from these participants with their excitation-emission matrices in order to identify the cell types contributing to the signal.
OUTLINE: Participants undergo placement of a fiber optic probe on one normal columnar cell site and one normal squamous cell site of the cervix during colposcopy*. The probe delivers laser light at a specific excitation wavelength and collects fluorescence from the entire emission wavelength range from the mucosa. Participants undergo biopsies of both sites.
NOTE: *The columnar epithelium will not be colposcopically visible in all patients, in which case 2 normal squamous sites will be measured
PROJECTED ACCRUAL: A total of 1,000 participants will be accrued for this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer, Precancerous Condition
Keywords
cervical cancer, cervical intraepithelial neoplasia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1070 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fluorescence Spectroscopy
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Colposcopic biopsy
Other Intervention Name(s)
biopsy
Intervention Description
Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
Intervention Type
Procedure
Intervention Name(s)
Light-Scattering Spectroscopy
Other Intervention Name(s)
Spectroscopy, Fluorescence spectroscopy
Intervention Description
Spectroscopy readings taken in 2 regions of cervix.
Primary Outcome Measure Information:
Title
Fluorescent Measurements of Cervix
Description
Two fluorescent measurements of cervix, approximately 2.5 minutes each: 1)colposcopically normal columnar site, and 2) a colposcopically normal squamous site.
Time Frame
Participation complete after readings of several 2.5 minutes fluorescent measurements and biopsies taken during colposcopy.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects will be individuals 18 years of age or older, who have voluntarily responded to advertisement in the form of posted flyers or word of mouth.
Subjects must sign an informed consent indicating awareness of the investigational nature of this study.
Exclusion Criteria:
1) Pregnant individuals will be ineligible for this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helen Rhodes, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
M. D. Anderson Cancer Center at University of Texas
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Facility Name
British Columbia Cancer Agency - Vancouver Cancer Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
12. IPD Sharing Statement
Links:
URL
http://www.mdanderson.org
Description
UT MD Anderson Cancer Center Website
Learn more about this trial
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
We'll reach out to this number within 24 hrs